Cargando…

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies

In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main “problem” that comes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantinescu, Catalin, Pasca, Sergiu, Zimta, Alina-Andreea, Tat, Tiberiu, Rus, Ioana, Teodorescu, Patric, Iluta, Sabina, Tanase, Alina, Colita, Anca, Sigurjonsson, Olafur, Einsele, Hermann, Tomuleasa, Ciprian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565707/ https://www.ncbi.nlm.nih.gov/pubmed/32911829 http://dx.doi.org/10.3390/jcm9092903

Ejemplares similares

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician
por: Constantinescu, Catalin, et al.
Publicado: (2019)

B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?
por: Desmirean, Minodora, et al.
Publicado: (2020)

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
por: Deak, Dalma, et al.
Publicado: (2019)

The Malignant Role of Exosomes as Nanocarriers of Rare RNA Species
por: Zimta, Alina-Andreea, et al.
Publicado: (2020)

A narrative review of central nervous system involvement in acute leukemias
por: Deak, Dalma, et al.
Publicado: (2021)

The Predictive Role of Modified Early Warning Score in 174 Hematological Patients at the Point of Transfer to the Intensive Care Unit
por: Constantinescu, Catalin, et al.
Publicado: (2021)

The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients
por: Pasca, Sergiu, et al.
Publicado: (2020)

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
por: Radu, Letitia-Elena, et al.
Publicado: (2020)

Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies
por: Cenariu, Diana, et al.
Publicado: (2022)

Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
por: Colita, Andrei, et al.
Publicado: (2023)

SERS-Based Evaluation of the DNA Methylation Pattern Associated With Progression in Clonal Leukemogenesis of Down Syndrome
por: Moisoiu, Vlad, et al.
Publicado: (2021)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma
por: Deak-Mihaly, Dalma, et al.
Publicado: (2021)

Targeting the Microenvironment in MDS: The Final Frontier
por: Teodorescu, Patric, et al.
Publicado: (2020)

Approach to the Adult Acute Lymphoblastic Leukemia Patient
por: Sas, Valentina, et al.
Publicado: (2019)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation
por: Colita, Andrei, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP
por: Iluta, Sabina, et al.
Publicado: (2020)

Current therapeutic approaches in the management of hemophilia—a consensus view by the Romanian Society of Hematology
por: Hotea, Ionut, et al.
Publicado: (2021)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Extramedullary Hematopoiesis of the Liver and Spleen
por: Cenariu, Diana, et al.
Publicado: (2021)

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

Correlation between the prevalence of T-cell lymphomas and alcohol consumption
por: Desmirean, Minodora, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience
por: Tanase, Alina D., et al.
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology
por: Moisoiu, Vlad, et al.
Publicado: (2019)

Design and preclinical testing of an anti‐CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
por: Tigu, Adrian Bogdan, et al.
Publicado: (2023)

Genetically enhanced T lymphocytes and the intensive care unit
por: Tat, Tiberiu, et al.
Publicado: (2018)

Correction: Genetically enhanced T lymphocytes and the intensive care unit
por: Tat, Tiberiu, et al.
Publicado: (2018)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia
por: Marcu, Andra, et al.
Publicado: (2020)

Characterization of extrachromosomal circular DNA in patients with acute myeloid leukemia: proof-of-concept report using cohorts from Beijing and Shanghai
por: Qian, Liren, et al.
Publicado: (2022)

Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
por: Iluta, Sabina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u9j9into7sobtbfd3fvvkihoin